PYC Therapeutics (ASX:PYC) completed the retail component of its pro rata accelerated non-renounceable entitlement offer of new shares, raising about AU$47 million at AU$1.50 apiece, according to a Wednesday filing with the Australian bourse.
The company received applications for roughly 31 million shares, representing a take-up rate of 40%, the filing said.
This comes after the institutional component of the entitlement offer and placement, which raised about AU$537 million, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.